Sana Biotechnology (SANA) to Release Earnings on Thursday

Sana Biotechnology (NASDAQ:SANA) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $2.56 on Wednesday. The firm has a market cap of $571.57 million, a price-to-earnings ratio of -1.83 and a beta of 1.60. The company has a 50 day moving average price of $2.86 and a 200-day moving average price of $3.41. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50.

Insider Activity at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This trade represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SANA shares. HC Wainwright lifted their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.